
|Articles|August 18, 2016
EndoPredict vs Oncotype DX for Predicting Breast Cancer Recurrence
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses a recent study that compared EndoPredict and Oncotype DX, which both predict the likelihood of a breast cancer recurrence.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Frontline Sunvozertinib Improves PFS vs Chemotherapy in EGFR+ NSCLC
2
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
3
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
4
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis
5























































